The pharmaceutical company Amgen argues that Colorado's price cap interferes with federal patent law. philipdyer/iStock via ...

Earlier in July, a federal judge blocked Colorado’s plan to impose a 70% price cap on Amgen’s blockbuster arthritis drug ...

Judge says Amgen likely to face significant, irreparable harm Enbrel price was capped at $31,200 annually, list price tops $100,000 Colorado declined to comment In granting a preliminary injunction, ...

A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen ...

Colorado recently attempted to throw a financial lifeline to patients struggling with autoimmune conditions by aggressively ...

In 2024, the Colorado Prescription Drug Affordability Review Board declared Enbrel unaffordable, and last year it set an “upper payment limit” of about $31,000 per year.

A patent fight has already delayed Sandoz' biosimilar version of Amgen's anti-inflammatory blockbuster Enbrel. And now, it looks as if Sandoz will have to wait a little longer for a clear shot at the ...

A state board in Colorado is working to make history by becoming the first in the country to cap the price of a drug it deems unaffordable. Amid an aggressive industry lobbying campaign, Colorado ...